Study of ASTARTE Probiotic Capsules to Reduce Risk Factors for Recurrent Urinary Tract Infection in Women Aged 18 to 40
Led by Hvidovre University Hospital · Updated on 2022-09-23
720
Participants Needed
1
Research Sites
173 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the effect of a dietary supplement called ASTARTE17, which contains four probiotic strains Lactobacillus crispatus, L. rhamnosus, L. jensenii, and L. gasseri, on the microbiome in the intestine and vagina. The study focuses on women aged 18 to 40 years who have recurrent urinary tract infections rUTI. The goal is to see if ASTARTE17 can reduce risk factors for rUTI, measured by the number of symptomatic UTIs over six months.
Participants will take one capsule daily for six months. One group will receive the ASTARTE17 probiotic capsules, while the other group will receive placebo capsules identical in appearance but without the probiotic strains. The study is randomized and double-blind, meaning neither participants nor researchers know who receives which capsules. The study will map bacterial composition in urine, feces, and vaginal samples to examine relationships between microbiota and urinary tract infections.
During the study, participants will be monitored for urinary tract infection occurrences and changes in the vaginal and gut microbiome at six and twelve months. Researchers will collect samples and evaluate symptoms and the number of infections. The study also includes safety monitoring and follows participants for up to two years, with the primary outcome being the reduction of UTI cases after six months of treatment.
CONDITIONS
Brief Title
The Effect of ASTARTE™ on Recurrent Urinary Tract Infection
Research Team
A
Andreas Petersen, DM. PhD
K
Khaled Ghathian, phd.stud.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Have recurrent urinary tract infections (at least 2 within 6 months or more than 3 within one year)
Have been informed about the trial protocol
Able to follow the study protocol, provide voluntary consent, and sign the consent form
You will not qualify if you...
Currently pregnant or planning to become pregnant
Breastfeeding
Participated in another probiotic trial within the last 30 days
Allergic or hypersensitive to any ingredient in the study product
Mainly admitted for a condition other than urinary tract infection
Receiving antibiotic treatment for any condition other than urinary tract infection within the last 30 days
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 6 months
Participants take one capsule daily of either ASTARTE™ probiotic or placebo for 6 months.
Monthly visits during treatment
Follow-up
Duration - 6 months
Participants are monitored for urinary tract infection symptoms and microbiome changes after treatment ends.
Quarterly visits during follow-up
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Similar Trials
Study of D-mannose Daily Supplement to Prevent Recurrent Urinary Tract Infections in Post-menopausal Women Aged 55 to 85
Preventing Recurrent Urinary Tract Infections in Women Using Faecal Microbiota Transplantation
A Phase 2 and 3 Randomized, Triple-Blind Study
Study Comparing Hyaluronic Acid-Chondroitin Sulfate Bladder Treatment Versus Nitrofurantoin Antibiotics to Prevent Recurrent Urinary Tract Infections in Adult Women
Study of ASTARTE Probiotic Capsules to Reduce Risk Factors for Recurrent Urinary Tract Infection in Women Aged 18 to 40
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
The effect of the probiotic supplement-ASTARTE™-on the reduction of recurrent urinary tract infection in women aged 18-40 years: protocol for a randomized, double-blind, placebo-controlled study.
Khaled Saoud Ali Ghathian, Sofie Ingdam Halkjær, Karen Angeliki Krogfelt...